FibroBiologics Announces 2024 Annual Meeting of Stockholders
2024年5月16日 - 5:30AM
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
clinical-stage biotechnology company with 150+ patents issued and
pending with a focus on the development of therapeutics and
potential cures for chronic diseases using fibroblasts and
fibroblast-derived materials, today announced that its 2024 Annual
Meeting of Stockholders will take place on August 27, 2024, at 11
a.m. CDT, exclusively through a virtual format. The record date for
determination of stockholders entitled to vote at the annual
meeting is July 1, 2024.
About FibroBiologicsBased in
Houston, FibroBiologics is a cell therapy and regenerative medicine
company developing a pipeline of treatments and seeking potential
cures for chronic diseases using fibroblast cells and
fibroblast-derived materials. FibroBiologics holds 150+ US and
internationally issued patents/patents pending across various
clinical pathways, including disc degeneration, orthopedics,
multiple sclerosis, wound healing, reversing organ involution, and
cancer. FibroBiologics represents the next generation of medical
advancement in cell therapy. For more information,
visit www.FibroBiologics.com.
General
Inquiries:info@fibrobiologics.com
Investor Relations:Nic
JohnsonRusso Partners212-845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso
Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com
FibroBiologics (NASDAQ:FBLG)
過去 株価チャート
から 5 2024 まで 6 2024
FibroBiologics (NASDAQ:FBLG)
過去 株価チャート
から 6 2023 まで 6 2024